Literature DB >> 15944793

Simple mucin-type cancer associated antigens are pre-cancerous biomarkers during 1,2-dimethylhydrazine-induced rat colon carcinogenesis.

Edgardo Berriel1, Marcelo Hill, Juan J Barcia, Luis Ubillos, Mariela Gonzalez, Gisselle Detjen, Mariella Rondan, Héctor Navarrete, Eduardo Osinaga.   

Abstract

The simple mucin-type truncated O-glycans Tn (GalNAc-O-Ser/Thr) and sialyl-Tn (STn) antigens are useful diagnostic markers for human colon cancer. We herein report the characterization of 1,2-dimethylhidrazine (DMH)-induced colon cancer in rats as a new model for the study of aberrant O-glycosylation products during carcinogenesis. Evaluated by immunohistochemistry, both anti-Tn and anti-STn MAbs revealed no staining of normal colonic mucosa. On the contrary, Tn and STn were expressed by the first lesions detected following carcinogen administration (aberrant crypt foci), observing the most intense and uniform pattern in crypts with severe dysplasia. Adenocarcinomas with non-secreting components showed moderately and strong stain, but mucin-secreting carcinomas were mildly stained. The biochemical characterization of soluble Tn glycoproteins from ascitic fluids of rats with colon cancer revealed that Tn is bearing high molecular weight glycoproteins (containing sialic acid and/or GlcNAc and GalNAc), which migrated as two major components (one of approximately 220 kDa and other>500 kDa). Evaluated by CsCl gradient ultracentrifugation and perchloric acid precipitation, it was shown that Tn is carried for mucins. These results indicate that Tn and STn are pre-cancerous biomarkers in colon of rats treated with DMH. This model of rat colon cancer could be useful to study in vivo the temporal sequence of molecular events responsible for the deregulation of O-glycosylation pathways during colon carcinogenesis, and could contribute to improve the evaluation of diagnostic and therapeutic strategies based on the utilization of Tn and STn antigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944793

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer.

Authors:  Maha M Eissa; Cherine A Ismail; Mervat Z El-Azzouni; Amany A Ghazy; Mona A Hadi
Journal:  Invest New Drugs       Date:  2018-05-28       Impact factor: 3.850

Review 3.  Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers.

Authors:  Tongzhong Ju; Yingchun Wang; Rajindra P Aryal; Sylvain D Lehoux; Xiaokun Ding; Matthew R Kudelka; Christopher Cutler; Junwei Zeng; Jianmei Wang; Xiaodong Sun; Jamie Heimburg-Molinaro; David F Smith; Richard D Cummings
Journal:  Proteomics Clin Appl       Date:  2013-09-09       Impact factor: 3.494

4.  A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis.

Authors:  Marcelo Hill; Daniel Mazal; Verónica Andrea Biron; Laura Pereira; Luis Ubillos; Edgardo Berriel; Hafiz Ahmed; Teresa Freire; Mariella Rondán; Gerardo R Vasta; Fu-Tong Liu; María Mercedes Iglesias; Eduardo Osinaga
Journal:  J Histochem Cytochem       Date:  2010-03-02       Impact factor: 2.479

Review 5.  The Cosmc connection to the Tn antigen in cancer.

Authors:  Tongzhong Ju; Rajindra P Aryal; Matthew R Kudelka; Yingchun Wang; Richard D Cummings
Journal:  Cancer Biomark       Date:  2014-01-01       Impact factor: 4.388

Review 6.  The Roles of Glycans in Bladder Cancer.

Authors:  Yuli Jian; Zhongyang Xu; Chunyan Xu; Lin Zhang; Xiaoxin Sun; Deyong Yang; Shujing Wang
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

Review 7.  Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.

Authors:  Nora Berois; Alvaro Pittini; Eduardo Osinaga
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.